T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

Pharmaceutical

T3D Therapeutics

John Didsbury

Jessica Stanek

Hoda Gabriel

Blake Swearingen

Stan Chamberlain

Warren Strittmatter

The executive team at T3D Therapeutics has a history of working in the pharmaceutical industry and in medical research. They have experience leading companies and teams, and they have a strong educational background in the sciences.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at T3D Therapeutics

Board of Directors

Leadership Team